Mersana
Acquired
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2001
- Business Model
- B2B
- Website
- ir.mersana.com
- Total Funding
- $103.0M
- Last Round
- $33.0M Series CJun 2016
About
Mersana Therapeutics was a clinical-stage biopharmaceutical company focused on next-generation antibody-drug conjugates (ADCs) for cancer treatment, using its proprietary Dolasynthen and Immunosynthen ADC platforms. The company developed Emi-Le (emiltatug ledadotin), targeting B7-H4, for triple-negative breast cancer and other rare cancers. Mersana was acquired by Day One Biopharmaceuticals in January 2026.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account